Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study.
Antonio LlombartAntonio Anton-TorresBeatriz RojasRaquel AndrésNoelia MartinezCésar A RodríguezSara MarinTeresa PuértolasAlejandro Falcón GonzálezMaría Leonor Fernández-MurgaCarlos HagenManuel Ruiz-BorregoPublished in: Cancers (2023)
Use of the 21-gene test resulted in an overall 67% reduction in CT recommendation in patients considered candidates for CT. Our findings indicate the substantial potential of the 21-gene test to guide CT recommendations in patients with EBC considered to be at high risk of recurrence based on clinicopathological parameters, regardless of nodal status or treatment setting.
Keyphrases
- image quality
- computed tomography
- dual energy
- copy number
- genome wide
- contrast enhanced
- end stage renal disease
- early breast cancer
- genome wide identification
- ejection fraction
- newly diagnosed
- positron emission tomography
- chronic kidney disease
- lymph node
- high throughput
- dna methylation
- squamous cell carcinoma
- neoadjuvant chemotherapy
- clinical practice
- patient reported outcomes
- climate change